PubRank

Christopher M Blanchette

Author PubWeight™ 27.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Burden of concomitant asthma and COPD in a Medicaid population. Chest 2008 1.87
2 Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2014 1.52
3 Potential benefits and problems with computerized prescriber order entry: analysis of a voluntary medication error-reporting database. Am J Health Syst Pharm 2006 1.29
4 Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005 1.24
5 Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med 2010 1.10
6 Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008 1.06
7 Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis 2011 1.02
8 Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Appl Health Econ Health Policy 2014 0.98
9 Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin 2010 0.96
10 Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin 2009 0.96
11 Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008 0.95
12 Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverage. Health Serv Res 2008 0.94
13 Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther 2007 0.93
14 Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med 2010 0.93
15 The positive predictive value of a hyperkalemia diagnosis in automated health care data. Pharmacoepidemiol Drug Saf 2010 0.92
16 Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ 2009 0.90
17 Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010 0.87
18 Methylated Genes in Sputum Among Older Smokers With Asthma. Chest 2012 0.87
19 Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis. Clin Ther 2010 0.84
20 Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Pharmacother 2009 0.82
21 Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United States. J Asthma 2010 0.82
22 Assessing disparities in the receipt of inhaled corticosteroid prescriptions for asthma by Hispanic and non-Hispanic white patients. Ann Am Thorac Soc 2015 0.81
23 Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr Med Res Opin 2009 0.79
24 The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD management. Prim Care Respir J 2010 0.79
25 Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population. Am J Geriatr Pharmacother 2012 0.78
26 Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis 2010 0.77
27 Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia. Am J Health Syst Pharm 2008 0.77
28 Moderate symptom-based exacerbations as predictors of severe claims-based exacerbations in asthma. J Asthma 2013 0.76
29 Relationship between short-acting β2-adrenergic agonist use and healthcare costs. Am J Manag Care 2011 0.76
30 A cross-sectional retrospective analysis of the regionalization of complex surgery. BMC Surg 2014 0.75
31 Effects of skilled nursing facility structure and process factors on medication errors during nursing home admission. Health Care Manage Rev 2014 0.75
32 Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population. Curr Med Res Opin 2009 0.75
33 Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry 2015 0.75